Skip to main content

Jynarque, JYNARQUE

Unverified·never
Manufacturer
Otsuka
ICD-10 indication
Q61.3

Affordability Check

How much will you actually pay for Jynarque, JYNARQUE?

In 30 seconds, see every legitimate way to afford Jynarque, JYNARQUE — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Jynarque, JYNARQUE

What is this medication?

Jynarque is a prescription medicine that contains the active ingredient tolvaptan. It is specifically indicated to slow the decline of kidney function in adults who are at risk of rapidly progressing autosomal dominant polycystic kidney disease, often referred to as ADPKD. This genetic condition is characterized by the development of numerous fluid-filled cysts in the kidneys, which can cause the organs to enlarge and eventually lead to kidney failure. By slowing the rate of kidney function decline, the medication helps manage the progression of this chronic disease.

The medication works by acting as a selective vasopressin V2-receptor antagonist, which helps to reduce the growth and formation of kidney cysts. Because Jynarque carries a risk of serious and potentially fatal liver injury, it is only available through a restricted distribution program called the Jynarque REMS. Patients must undergo regular blood tests to monitor their liver health before and during treatment. Common side effects associated with the drug include increased thirst, frequent urination, and needing to urinate more often during the night.

Copay & patient assistance

  • Patient Copay Amount: As little as $0 per 28-day supply
  • Maximum Annual Benefit Limit: $9,200 (for 2025)
  • Core Eligibility Restrictions: Must have commercial insurance; not eligible if covered by any state or federal healthcare program (including Medicare Part D, Medicaid, Medigap, VA, DOD, or TRICARE); must be 18 years of age or older; must be a resident of the U.S. or Puerto Rico; cannot be combined with other offers or pharmacy benefit manager programs like "maximizers" or "accumulators"; specific state exclusions apply to Massachusetts (starting May 13, 2025) and California (starting August 13, 2025)
  • RxBIN, PCN, and Group numbers: Not Publicly Available (A physical copay card is not required as the benefit is applied directly through REMS-certified Specialty Pharmacies)

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Yes

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.